Phillip Aguila, MD
Pulmonary Disease · Martinsburg, WVNPI 1134157555
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,708 of the $21,279 with a category attached, or 69.1%. Regeneron Healthcare Solutions, Inc. accounts for 72.5% of it on its own, with 20 other manufacturers making up the rest. 2025 is the largest year on record at $16,314, more than ten times the $15 reported in 2019. Among pulmonary disease clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 241 payments — averaging $88.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$15K
- Intuitive Surgical$1K
- AstraZeneca$984
- GSK$958
- Inspire Medical Systems, Inc.$676
- Takeda Pharmaceuticals U.S.A., Inc.$432
- plus $2K from 15 others
What the payments were for
- Speaking & faculty fees$14,70869%
- Travel & lodging$1,2016%
- Food & beverage$5,21425%
- Education$1551%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 33 | $15,425 |
| Intuitive Surgical | 15 | $1,251 |
| AstraZeneca | 45 | $984 |
| GSK | 47 | $958 |
| Inspire Medical Systems, Inc. | 17 | $676 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $432 |
| Baxter Healthcare | 9 | $210 |
| Olympus Corporation Of The Americas | 2 | $202 |
| Electromed, Inc. | 10 | $184 |
| Amgen | 10 | $181 |
| Actelion Pharmaceuticals US, Inc. | 4 | $168 |
| Merck | 5 | $127 |
| Viatris Specialty LLC | 5 | $118 |
| Boehringer Ingelheim | 5 | $111 |
| Grifols USA, LLC | 4 | $79 |
| Verona Pharma, Inc. | 3 | $64 |
| Pulmonx Corporation | 1 | $28 |
| United Therapeutics Corporation | 1 | $24 |
| Tactile Systems Technology Inc | 1 | $21 |
| Mylan Specialty L.p. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$14,708
- Da Vinci Surgical System$885
- Inspire$324
- SINGLE USE SUCTION VALVE (Sterile)$150
- FASENRA$125
How this compares
$21,279 in reported general payments places this provider in the 90th percentile of 89 pulmonary disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 816 | $622,763 |
| Dupixent PenDupilumab | 49 | $216,422 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 234 | $187,464 |
| Spiriva RespimatTiotropium Bromide | 233 | $172,497 |
| OfevNintedanib Esylate | 14 | $159,713 |
| NucalaMepolizumab | 26 | $99,011 |
| SymbicortBudesonide/Formoterol Fumarate | 201 | $74,688 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 117 | $74,597 |
| Spiriva HandihalerTiotropium Bromide | 95 | $72,684 |
| Breo ElliptaFluticasone/Vilanterol | 89 | $48,895 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 88 | $44,272 |
| Advair HfaFluticasone Propion/Salmeterol | 78 | $34,840 |
| Incruse ElliptaUmeclidinium Bromide | 68 | $29,870 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 810 | $28,068 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 45 | $25,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $958 | $857,9021,121 claims |
| Boehringer IngelheimSpiriva Respimat, Ofev, Stiolto Respimat, Combivent Respimat | $111 | $432,495409 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $984 | $278,562467 claims |
| MerckDulera | $127 | $24,29457 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 89 pulmonary disease providers in West Virginia.
Other pulmonary disease in Martinsburg
- Houssein YounessMartinsburg$10K
- Feroz NooriMartinsburg$3K
- Richard CatlettMartinsburg$3K
- Hafiz Muhammad ZubairMartinsburg$2K
- Melvin SaludesGlen Dale$255K
- Roger AbrahamsMorgantown$133K
- Maria BoustaniBeckley$95K
- Ramzi HaddadinBeckley$43K
- Salam RajjoubBridgeport$29K
- Peter KochupuraMorgantown$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.